Literature DB >> 15681752

Immune regulation in the intestine: a balancing act between effector and regulatory T cell responses.

Fiona Powrie1.   

Abstract

The immune system in the intestine must respond rapidly to invading pathogens without mounting sustained effector cell responses to the indigenous commensal bacteria. Results from this laboratory using the T cell transfer model of colitis suggest that specialized populations of regulatory T cells control the immune response in the intestine. Regulatory T (Tr) cell activity is enriched within the naturally arising CD4(+) CD25(+) Tr subset that has been shown to prevent a number of inflammatory diseases. CD4(+) CD25(+) Tr cells control intestinal inflammation induced by both innate and adaptive immune responses via IL-10- and TGF-beta-dependent mechanisms. Recent results have shown that CD4(+) CD25(+) Tr cells can cure established colitis, suggesting their utility for the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Year:  2004        PMID: 15681752     DOI: 10.1196/annals.1309.030

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  Differential angiogenic regulation of experimental colitis.

Authors:  John H Chidlow; Will Langston; James J M Greer; Dmitry Ostanin; Maisoun Abdelbaqi; Jeffery Houghton; Annamalai Senthilkumar; Deepti Shukla; Andrew P Mazar; Matthew B Grisham; Christopher G Kevil
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

2.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

Review 3.  Epithelia: lymphocyte interactions in the gut.

Authors:  Stephanie Dahan; Franziska Roth-Walter; Paul Arnaboldi; Shradha Agarwal; Lloyd Mayer
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

4.  Visualization of IL-22-expressing Lymphocytes Using Reporter Mice.

Authors:  Wei Shen; Wenqing Li; Julie A Hixon; Caroline Andrews; Scott K Durum
Journal:  J Vis Exp       Date:  2017-01-25       Impact factor: 1.355

5.  Relationship between various Chinese medicine types and T-cell subsets in patients with ulcerative colitis.

Authors:  Ting-min Chang; Xiu-min Li; Xi-de Zhao
Journal:  Chin J Integr Med       Date:  2009-07-02       Impact factor: 1.978

6.  Evidence for dendritic cell-dependent CD4(+) T helper-1 type responses to commensal bacteria in normal human intestinal lamina propria.

Authors:  Rawleigh Howe; Stephanie Dillon; Lisa Rogers; Martin McCarter; Caleb Kelly; Ricardo Gonzalez; Nancy Madinger; Cara C Wilson
Journal:  Clin Immunol       Date:  2009-01-25       Impact factor: 3.969

7.  Development of fatal colitis in FVB mice infected with Citrobacter rodentium.

Authors:  Diana Borenshtein; Prashant R Nambiar; Elizabeth B Groff; James G Fox; David B Schauer
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

8.  Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.

Authors:  Anthony B Nesburn; Ilham Bettahi; Gargi Dasgupta; Alami Aziz Chentoufi; Xiuli Zhang; Sylvaine You; Naoyuki Morishige; Andrew J Wahlert; Donald J Brown; James V Jester; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

Review 9.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

10.  Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.

Authors:  Rainer Glauben; Elena Sonnenberg; Martin Wetzel; Paolo Mascagni; Britta Siegmund
Journal:  J Biol Chem       Date:  2014-01-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.